Carbimazole embryopathy: an emerging phenotype.

Abstract

Concerns about the safety of carbimazole in pregnancy were raised in 1985. Since this time many reports of children believed to have been affected by carbimazole in utero have appeared in the medical literature. Initial reports were of an increased incidence of scalp defects in the infants of treated mothers, but many other anomalies have now been described. Choanal atresia, gastrointestinal anomalies-particularly esophageal atresia, athelia/hypothelia, developmental delay, hearing loss, and dysmorphic facial features have all been reported. The phenotype associated with exposure to carbimazole appears to be rare but specific with distinctive facial features. We report on two new cases of carbimazole embryopathy with strikingly similar facial features.

• Authors: Nicola Foulds, Ian Walpole, Frances Elmslie, Sahar Mansour
• Journal: American journal of medical genetics. Part A (Am J Med Genet A) Vol. 132A Issue 2 Pg. 130-5 (Jan 15 2005) ISSN: 1552-4825 [Print] United States
• PMID: 15578620 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Antithyroid Agents
• Carbimazole

Topics

• Abnormalities, Drug-Induced (etiology, pathology)
• Adolescent
• Antithyroid Agents (adverse effects, therapeutic use)
• Carbimazole (adverse effects, therapeutic use)
• Child
• Ear (abnormalities)
• Eyebrows (abnormalities)
• Female
• Humans
• Hyperthyroidism (drug therapy)
• Nose (abnormalities)
• Pregnancy
• Pregnancy Complications (drug therapy)
• Thyrotoxicosis (drug therapy)